How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Impetigo: antimicrobial prescribing

reserved. Subject to Notice of rights ( conditions#notice-of-rights). Page 24 of 28• there were more incidences of diarrhoea in children taking oral erythromycin compared with oral amoxicillin • there were more incidences of stomach ache, rash, fever or vomiting but fewer incidents of diarrhoea in adults, young people and children taking oral cefadroxil compared with oral flucloxacillin. No safety or tolerability data were reported for the other comparisons. Dual

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Interim guidance: public health management of cases and contacts associated with novel coronavirus (COVID-19) in the community

coronaviruses have emerged in recent years: SARS-CoV (2002) and MERS-CoV (2012). In late 2019, a novel coronavirus related to a cluster of pneumonia cases in Wuhan, China (COVID-19) was identified. CLINICAL SYMPTOMS Clinical symptoms of COVID-19 may be mild or severe. Mild symptoms may include some or all of the following: Low-grade fever, cough, malaise, rhinorrhoea, fatigue, sore throat, gastro-intestinal symptoms such as nausea, vomiting, and/or diarrhoea. More severe symptoms may include any (...) , such as persistent coughing and sneezing, or had diarrhea or vomiting during the flight. In the event that a crew member is a confirmed case and was symptomatic during the flight, passengers seated in the area served by that crew members, as well as the other crew members, should be traced. Version: March 10, 2020 17 References i WHO. Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts. [Online] 4 February 2020. [Accessed on 7 February

2020 CPG Infobase

4. Rotarix oral vaccine: wrong-route errors

; this leads to confusion. The Pharmacovigilance Centre in Tours, France, reported 4 cases of intramuscular administration of Rotarix° vaccine in France between November 2014 and April 2017. In two cases, infants experienced serious adverse reactions with diarrhoea and the presence of blood in the stools. There have been no reported cases of injection by mistake with Rotateq° vaccine, which is a ready-to-use oral solution in a small, single-dose tube with a mouthpiece clearly designed for oral

2020 Prescrire

6. Optimisation of RIZIV – INAMI lump sums for incontinence

of neurological conditions such as different forms of paralysis, spina bifida, stroke, multiple sclerosis, motor neurone disease, but also diabetes. Patients can have UUI or dysfunction of sphincter(s) with or without FI. Neurological disorders affecting the brain, spinal cord, or the peripheral nervous system have FI due to impaired anal sphincter control, reduced or absent anorectal sensibility, or abnormal anorectal reflexes. Diabetic patients can have neuropathy of the anal canal or chronic diarrhoea (...) surgery • Perianal fistulas • Hirschprung disease • Sexual abuse Cause of faecal incontinence Underlying pathology Rectal disorders • Inflammatory bowel disease • Radiation therapy • Rectocoele • Rectal intersusception • Rectal prolapse • Faecal impaction • Rectal surgery Myopathy • Systemic scleroderma Fast colorectal transit time • Chronic diarrhoea • Irritable bowel syndrome Psychological • Encopresis • Dementia KCE Report 304 Incontinence 25 Frail elderly and the cognitively impaired

2020 Belgian Health Care Knowledge Centre

8. Hepatitis C Virus Infection in Adolescents and Adults: Screening

events were fatigue, headache, nausea, and diarrhea. Seven nonrandomized, open-label trials (n = 300) in adolescents examined treatment harms. Five trials reported no withdrawals due to adverse events; 1 trial reported a serious adverse event (grade 3 joint injury). The rate of any adverse event was 27% in 1 trial and 71% to 84% in 4 trials. Specific adverse event rates across trials ranged from 3% to 48% for headache (7 trials), 5% to 53% for fatigue (7 trials), and 3% to 28% for gastrointestinal (...) adverse events (nausea, vomiting, or diarrhea) (5 trials). Three trials reported no deaths in adolescents (n = 182) treated with DAA regimens. These trials were not designed to evaluate long-term harms associated with DAA treatment during adolescence. Response to Public Comment A draft version of this recommendation statement was posted for public comment on the USPSTF website from August 27 to September 23, 2019. Some comments asked for a definition of “high risk”; however, an extensive list of risk

2020 U.S. Preventive Services Task Force

9. Pharmacologic management of alcohol use disorder: worth a shot?

for acamprosate or naltrexone on mortality 1,4,5 or quality of life. 1 o Most common adverse effects: ? Naltrexone: 3,5 • Nausea: 26% versus 16% placebo number needed to harm (NNH)=10. • Sleepiness: 21% versus 16% placebo, NNH=20. ? Acamprosate: 4 • Diarrhea: 16% versus 10% placebo, NNH=17. • Incidence decreases after first four weeks of treatment. Context: • Guidelines suggest first line pharmacotherapy include acamprosate for abstinence or naltrexone for a goal of reduced drinking or abstinence. They also

2020 Tools for Practice

11. Blinatumomab (Blincyto) - treatment of adults with Philadelphia chromosome negative, CD19 positive, B-precursor acute lymphoblastic leukaemia (ALL)

%), tremor (30%), chills (26%), fatigue (24%), nausea (23%), vomiting (22%), diarrhoea (20%), hypokalaemia (16%), neutropenia (16%), insomnia (15%), aphasia (13%), arthralgia (13%), cough (13%), hypotension (12%), and constipation (11%). Treatment-emergent serious adverse events reported in =5% of patients were pyrexia (15%), tremor (6.9%), aphasia (5.2%) and encephalopathy (5.2%). 2 Summary of clinical effectiveness issues ALL is an aggressive form of cancer that specifically affects immature

2020 Scottish Medicines Consortium

12. Lorlatinib (Lorviqua) - non-small cell lung cancer (NSCLC)

1001 included all patients who received at least one dose of lorlatinib 100mg, n=295. All patients reported at least one adverse event, almost all of these were considered treatment-related. The following treatment-related adverse events were reported: hypercholesterolemia (84%), hypertriglyceridemia (67%), oedema (55%), peripheral neuropathy (48%), fatigue (28%), cognitive effects (29%), weight gain (26%), mood effects (23%), diarrhoea (23%) and vision disorders (15%). The most common Grade 3 or 4

2020 Scottish Medicines Consortium

14. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (Abstract)

). In patients with PIK3CA/AKT1/PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade ≥ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%).Addition of the AKT inhibitor capivasertib

2020 EvidenceUpdates

15. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201 (Abstract)

(PFS) and overall survival (OS) in all patients treated with FOLFOX compared with IT, stratified by low and high ERCC1 levels, and to assess for interactive effects between ERCC1 expression and treatment arm.Eighty-six percent of patients had ERCC1 values < 1.7. Thus, evaluation of the ERCC1-high subgroup was limited. Grade ≥ 3 anemia, dehydration, diarrhea, and fatigue were greater in patients with IT. Occurrences of grade ≥ 3 neuropathy and decreased neutrophils were greater in patients

2020 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>